{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:48:34Z","timestamp":1791413314047,"version":"4.3.3"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972864"],"award-info":[{"award-number":["81972864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172720"],"award-info":[{"award-number":["82172720"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China","doi-asserted-by":"publisher","award":["2019KJL001"],"award-info":[{"award-number":["2019KJL001"]}],"id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The purpose of this study was to investigate the predictive value of tumor metabolic parameters in combination with secondary lymphoid metabolic parameters on positron emission tomography (PET)\/computed tomography (CT) for immune checkpoint inhibitor (ICI) prognosis in advanced lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study retrospectively included 125 patients who underwent 18F-fludeoxyglucose (FDG) PET\/CT before ICI therapy, including 41 patients who underwent a second PET\/CT scan during ICI treatment. The measured PET\/CT parameters included tumor metabolism parameters [maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), total lesion glycolysis (TLG), and total metabolic tumor volume (TMTV)] and secondary lymphoid organ metabolism parameters [spleen-to-liver SUVmax ratio (SLR) and bone marrow-to-liver SUVmax ratio (BLR)]. The correlation of PET\/CT metabolic parameters with early ICI treatment response, progression-free survival (PFS), and overall survival (OS) was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within a median follow-up of 28.7 months, there were 44 responders and 81 non-responders. The median PFS was 8.6 months (95% confidence interval (CI): 5.872\u201311.328), and the median OS was 20.4 months (95% CI: 15.526\u201325.274). Pretreatment tumor metabolic parameters were not associated with early treatment responses. The high bone marrow metabolism (BLR &amp;gt;1.03) was significantly associated with a shorter PFS (p = 0.008). Patients with a high TMTV (&amp;gt;168 mL) and high spleen metabolism (SLR &amp;gt;1.08) had poor OS (p = 0.019 and p = 0.018, respectively). Among the 41 patients who underwent a second PET\/CT scan, the \u0394SUVmax was significantly lower (p = 0.01) and the SLR was significantly higher (p = 0.0086) in the responders. Populations with low-risk characteristics (low TMTV, low SLR, and \u0394SLR &amp;gt; 0) had the longest survival times.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High pretreatment TMTV and SLR are associated with poor OS, and increased spleen metabolism after ICI therapy predicts treatment benefit. This indicates that the combination of tumor and spleen metabolic parameters is a valuable prognostic strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.1004351","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T02:10:01Z","timestamp":1666318201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Peng","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-Small-Cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2020.11.013","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)","volume":"152","author":"Lu","year":"2021","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03136","article-title":"Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-Small-Cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2020.1701439","article-title":"Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations","volume":"14","author":"Reck","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11307-018-1181-3","article-title":"The evolving role of FDG-PET\/CT in the diagnosis, staging, and treatment of breast cancer","volume":"21","author":"Paydary","year":"2019","journal-title":"Mol Imaging Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/1874471013666191230144821","article-title":"18F-FDG PET\/CT in restaging and evaluation of response to therapy in lung cancer: State of the art","volume":"13","author":"Castello","year":"2020","journal-title":"Curr Radiopharmaceuticals"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-020-01539-7","article-title":"FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer","volume":"34","author":"Seban","year":"2020","journal-title":"Ann Nucl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"47","author":"Seban","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/pap.0000000000000219","article-title":"Paget\u2019s \u201cSeed and soil\u201d theory of cancer metastasis: An idea whose time has come","volume":"26","author":"Akhtar","year":"2019","journal-title":"Adv anatomic Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04411-7","article-title":"Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics","volume":"46","author":"Seban","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.06.028","article-title":"PET\/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy","volume":"520","author":"Jin","year":"2021","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European journal of cancer (Oxford, England: 1990)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/diagnostics11020210","article-title":"PET-based volumetric biomarkers for risk stratification of non-small cell lung cancer patients","volume":"11","author":"Pellegrino","year":"2021","journal-title":"Diagnostics (Basel Switzerland)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2903-7","article-title":"Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: A meta-analysis","volume":"42","author":"Im","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/mnm.0000000000001025","article-title":"18F-FDG PET\/CT in non-small-cell lung cancer patients: A potential predictive biomarker of response to immunotherapy","volume":"40","author":"Evangelista","year":"2019","journal-title":"Nucl Med Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/jcm9030725","article-title":"Potential of FDG-PET as prognostic significance after anti-PD-1 antibody against patients with previously treated non-small cell lung cancer","volume":"9","author":"Hashimoto","year":"2020","journal-title":"J Clin Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3390\/cancers13071634","article-title":"Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (NSCLC): A real world experience","volume":"13","author":"Monaco","year":"2021","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000645","article-title":"Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: A prospective study","volume":"8","author":"Chardin","year":"2020","journal-title":"J Immunotherapy Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.3390\/cancers13133117","article-title":"The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (NSCLC) in radiological progression during treatment with nivolumab","volume":"13","author":"Bauckneht","year":"2021","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-017-0779-x","article-title":"Relationship between reticuloendothelial systems\u2019 FDG uptake level and clinicopathological features in patient with invasive ductal breast cancer","volume":"122","author":"\u015eahin","year":"2017","journal-title":"La Radiologia Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13550-020-00660-y","article-title":"[(18)F]FDG uptake of bone marrow on PET\/CT for predicting distant recurrence in breast cancer patients after surgical resection","volume":"10","author":"Lee","year":"2020","journal-title":"EJNMMI Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04500-7","article-title":"New insight on the correlation of metabolic status on (18)F-FDG PET\/CT with immune marker expression in patients with non-small cell lung cancer","volume":"47","author":"Wang","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/s41598-021-81298-1","article-title":"Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer","volume":"11","author":"Shimura","year":"2021","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41467-020-15186-z","article-title":"Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies","volume":"11","author":"Mabuchi","year":"2020","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/bf02470555","article-title":"Role of the spleen on immunosuppression in esophageal and gastric cancer","volume":"16","author":"Toge","year":"1986","journal-title":"Japanese J Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201041069","article-title":"In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site","volume":"41","author":"Haverkamp","year":"2011","journal-title":"Eur J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1230578","article-title":"TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function","volume":"5","author":"Spinetti","year":"2016","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1113744109","article-title":"Origins of tumor-associated macrophages and neutrophils","volume":"109","author":"Cortez-Retamozo","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05780-2","article-title":"Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [(18)F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0","volume":"49","author":"Lopci","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324048","article-title":"Activated akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma","volume":"33","author":"Rathmell","year":"2003","journal-title":"Eur J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2833","article-title":"TLR-driven early glycolytic reprogramming via the kinases TBK1-IKK\u03b5 supports the anabolic demands of dendritic cell activation","volume":"15","author":"Everts","year":"2014","journal-title":"Nat Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2967\/jnumed.117.193011","article-title":"(18)F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor","volume":"59","author":"Dercle","year":"2018","journal-title":"J Nucl Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00262-018-2279-9","article-title":"Can benign lymphoid tissue changes in (18)F-FDG PET\/CT predict response to immunotherapy in metastatic melanoma","volume":"68","author":"Sachpekidis","year":"2019","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7150\/thno.35989","article-title":"Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo (18)F-FDG-PET","volume":"10","author":"Schwenck","year":"2020","journal-title":"Theranostics"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2014.06.021","article-title":"Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting","volume":"22","author":"Villaverde","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2011.01.126","article-title":"A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer","volume":"81","author":"Qu","year":"2012","journal-title":"Eur J Radiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.14735\/amko20173S32","article-title":"[Comparison of RECIST 1.1 and iRECIST for response evaluation in solid tumours]","volume":"30","author":"Houdek","year":"2017","journal-title":"Klinicka onkologie: casopis Ceske Slovenske onkologicke spolecnosti"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000146","article-title":"Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis","volume":"8","author":"Mulkey","year":"2020","journal-title":"J Immunotherapy Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04625-9","article-title":"Radiomics of (18)F-FDG PET\/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy","volume":"47","author":"Mu","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01929","article-title":"Circulating tumor DNA minimal residual disease detection of non-Small-Cell lung cancer treated with curative intent","volume":"40","author":"Pellini","year":"2022","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/cancers12020487","article-title":"Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors","volume":"12","author":"Castello","year":"2020","journal-title":"Cancers"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1004351\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T02:10:05Z","timestamp":1666318205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1004351\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2022.1004351"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1004351","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"article-number":"1004351"}}